![]() |
Name |
Cyclo(glycyltryptophyl)
|
Molecular Formula | C13H13N3O2 | |
IUPAC Name* |
(3S)-3-(1H-indol-3-ylmethyl)piperazine-2,5-dione
|
|
SMILES |
C1C(=O)N[C@H](C(=O)N1)CC2=CNC3=CC=CC=C32
|
|
InChI |
InChI=1S/C13H13N3O2/c17-12-7-15-13(18)11(16-12)5-8-6-14-10-4-2-1-3-9(8)10/h1-4,6,11,14H,5,7H2,(H,15,18)(H,16,17)/t11-/m0/s1
|
|
InChIKey |
IFQZEERDQXQTLJ-NSHDSACASA-N
|
|
Synonyms |
Cyclo(-Gly-Trp); Cyclo(glycyltryptophyl); 7451-73-2; (S)-3-((1H-Indol-3-yl)methyl)piperazine-2,5-dione; CHEBI:69031; (3S)-3-(1H-indol-3-ylmethyl)piperazine-2,5-dione; CYCLO(TRP-GLY); Cyclo(glycyl-L-tryptophan); Cyclo(-Trp-Gly); Cyclo(Gly-Trp-); CHEMBL226544; SCHEMBL3120523; ZINC1865980; MFCD00083708; CS-0208968; Q27137374
|
|
CAS | NA | |
PubChem CID | 6997508 | |
ChEMBL ID | CHEMBL226544 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 243.26 | ALogp: | 0.8 |
HBD: | 3 | HBA: | 2 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 74.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 18 | QED Weighted: | 0.727 |
Caco-2 Permeability: | -4.877 | MDCK Permeability: | 0.00000798 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.014 |
Human Intestinal Absorption (HIA): | 0.24 | 20% Bioavailability (F20%): | 0.073 |
30% Bioavailability (F30%): | 0.955 |
Blood-Brain-Barrier Penetration (BBB): | 0.992 | Plasma Protein Binding (PPB): | 35.44% |
Volume Distribution (VD): | 0.789 | Fu: | 56.93% |
CYP1A2-inhibitor: | 0.125 | CYP1A2-substrate: | 0.122 |
CYP2C19-inhibitor: | 0.223 | CYP2C19-substrate: | 0.063 |
CYP2C9-inhibitor: | 0.103 | CYP2C9-substrate: | 0.503 |
CYP2D6-inhibitor: | 0.017 | CYP2D6-substrate: | 0.412 |
CYP3A4-inhibitor: | 0.165 | CYP3A4-substrate: | 0.089 |
Clearance (CL): | 5.712 | Half-life (T1/2): | 0.835 |
hERG Blockers: | 0.039 | Human Hepatotoxicity (H-HT): | 0.077 |
Drug-inuced Liver Injury (DILI): | 0.047 | AMES Toxicity: | 0.056 |
Rat Oral Acute Toxicity: | 0.461 | Maximum Recommended Daily Dose: | 0.702 |
Skin Sensitization: | 0.452 | Carcinogencity: | 0.066 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.013 |
Respiratory Toxicity: | 0.152 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004711 | ![]() |
0.632 | D05EJG | ![]() |
0.424 | ||
ENC001910 | ![]() |
0.610 | D0NG7O | ![]() |
0.333 | ||
ENC000975 | ![]() |
0.592 | D02DMQ | ![]() |
0.327 | ||
ENC004610 | ![]() |
0.592 | D09ZIO | ![]() |
0.319 | ||
ENC005470 | ![]() |
0.526 | D00YLW | ![]() |
0.312 | ||
ENC001912 | ![]() |
0.524 | D0U5RT | ![]() |
0.311 | ||
ENC004934 | ![]() |
0.524 | D05EPM | ![]() |
0.306 | ||
ENC004531 | ![]() |
0.524 | D0K0KH | ![]() |
0.299 | ||
ENC001911 | ![]() |
0.512 | D0U7GK | ![]() |
0.296 | ||
ENC005343 | ![]() |
0.495 | D03GET | ![]() |
0.294 |